All News

glomerulonephritis.GN_.lupus_.jpg

Voclosporin in SLE - Long-Term Safety and Efficacy

d Jack Cush, MD

The AURORA 2 study evaluated the long-term safety and efficacy of voclosporin lupus nephritis patients and, after three years, demonstrated long term safety and efficacy following the one-year AURORA 1 study.

Read Article
infx.pneumonia.jpg

Infectious Risk with B Cell Therapies in Lupus

d Jack Cush, MD

A UK registry study of moderate to severe systemic lupus erythematosus (SLE) patients showed that treatment with rituximab or belimumab was not associated with a greater risk of serious infection, when compared to standard of care therapy.

Read Article
RNase

RNase Treatment of Autoimmune Disorders

d Jack Cush, MD

U1RNP complex, Ro/SSA and La/SSB are major RNA-containing autoantigens associated with autoimmune disorders. Immune complexes (ICs) composed of RNA-containing autoantigens and autoantibodies are suspected to be involved in the pathogenesis of some systemic autoimmune diseases.

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

Danger with Hydroxychloroquine Nonadherence in SLE

d Jack Cush, MD

A large cohort study shows that severe non-adherence to hydroxychloroquine (HCQ) results in serious risks for SLE flares, damage, and mortality.

Read Article
vaccination.jpg

Hold the Methotrexate for One Week

d Jack Cush, MD

In 2018, Park et al showed optimal responses to influenza vaccination in RA patients was best achieved by holding methotrexate for 2 weeks following immunization, with improved humoral responses. Now, a followup trial suggests that equivalent results are had by holding MTX for only 1 week with the "flu" vaccine.

Read Article
pregn.outcome.jpg

SLE and Pregnancy Outcomes

d Jack Cush, MD

Obstetric complications and poor pregnancy outcomes are not uncommon in women with SLE, especially with active disease.  A large Spanish cohort trials shows that term pregnancy is more likely before the diagnosis of SLE and that poorer pregnancy outcomes were associated with antibody positivity to anticardiolipin IgG and anti-beta-2- glycoprotein IgG/IgM, but not lupus anticoagulant.

Read Article
PSA%20026.jpg

EULAR Points to Consider in Progressing Psoriasis to Psoriatic Arthritis

d Jack Cush, MD

The transition from psoriasis to PsA – and the early diagnosis of PsA – is of considerable scientific and clinical interest. People typically have psoriatic skin disease for a decade or more before they begin to experience the joint involvement of PsA.

Read Article
Danger with Hydroxychloroquine Nonadherence in SLE A large cohort study shows that severe non-adherence to hydroxychloroquine (HCQ) results in serious risks for SLE flares, damage, and mortality. https://t.co/RFPQZXQMeI https://t.co/eu1rhVyV18

Links:

Dr. John Cush RheumNow ( View Tweet)
SLE and Pregnancy Outcomes Obstetric complications and poor pregnancy outcomes are not uncommon in women with systemic lupus erythematosus (SLE), especially with active disease. https://t.co/BeCQYTq928 https://t.co/M6oILWfah1

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR Points to Consider in Progressing Psoriasis to Psoriatic Arthritis The transition from psoriasis to PsA – and the early diagnosis of PsA – is of considerable scientific and clinical interest. https://t.co/KYLBU3E0k6 https://t.co/oHgqEX8Gr6

Links:

Dr. John Cush RheumNow ( View Tweet)
Belgian study of 312 PsA & 213 SpA pts showed that most had normal spinal Xrays (87.5% PsA, 92% SpA). SpA pts had higher mSASSS than PsA (p<0.05). More Cx (73%) than Lumbar (33%) in PsA; SpA, CX (64%) & LS (71%) evenly distributed https://t.co/Z8JRRuxmWZ https://t.co/8uMiAsk7aA

Links:

Dr. John Cush RheumNow ( View Tweet)
Plantar Fasciitis study of 180 PF patients shows no clinically meaningful difference between pts treated with patient advice plus heel cup alone (PA) versus PA and lower limb exercise (PAX) versus PAX plus corticosteroid injection (PAXI) https://t.co/j4Cd42akx6 https://t.co/rQ6vZRw34A

Links:

Dr. John Cush RheumNow ( View Tweet)
Post hoc analysis 2 phase III RCTs of abatacept (Sc & IV) in 409 polyarticular JIA pcJIA. ABA was effective (by JIA-ACR and JADAS27 responses) & well tolerated, regardless of concomitant or prior MTX use. https://t.co/cTn52V5Fuu https://t.co/CUqin00LZh

Links:

Dr. John Cush RheumNow ( View Tweet)
Combination Cannabidiol (CBD) & hydroxychloroquine in RA? A phase II trial of IHL-675A (CBD+HCQ) will soon begin; following on phase I and animal studies showing it was tolerated, with no adverse events of concern.IHL-675A was superior to HCQ alone. https://t.co/HZYR7FA7i1 https://t.co/jvlot0OIw4

Links:

Dr. John Cush RheumNow ( View Tweet)
Nonprofit Allen Institute for Immunology will partner with researchers from Eli Lilly to investigate and profile disease state diversity and biomarkers for drug response in atopic dermatitis and rheumatoid arthritis https://t.co/nRbdWdFx7C https://t.co/rlngbtxgUo

Links:

Dr. John Cush RheumNow ( View Tweet)
Research from 12 states with medical cannabis laws looked at 583 820 adults w/ chronic noncancer pain. Data over 3 yres shows < 0.05% change in the use of opioid prescriptions, nonopioid prescriptions, pain meds, or chr pain procedures https://t.co/ArbP4xe4dH https://t.co/MPRBZNIIoS

Links:

Dr. John Cush RheumNow ( View Tweet)
Top 10-selling drugs accts for 22% of Medicare part D spending ($47.7/$215.7 billion) Eliquis $12.6 Billion Trulicity $4.7 B Januvia $4.1B Jardiance $3.7B Lantus $2.8B Ozempic $2.6B Revlimid $5.9B Xarelto $5.2B Imbruvica $3.2B Humira $2.9B https://t.co/5rvLldNLF0 https://t.co/OOt8he8Ig4

Links:

Dr. John Cush RheumNow ( View Tweet)
In AUSTRALIA, 30% (~ 7million) have a chronic #MSK condition, costing $14.6 billion (10% of all healthcare spending) in 2019-20. Overall, 4 million w/ back problems, 3 million arthritis, 900,000 osteoporosis, 450,000 w/ #RA. https://t.co/TDV50PoRXj https://t.co/EtSUuv6jMA

Links:

Dr. John Cush RheumNow ( View Tweet)
Filgotinib Effects on Semen and Sex Hormones The oral Janus kinase 1 inhibitor filgotinib is available worldwide, but not in the USA, where the FDA held up its approval for use in RA due to unfinished studies of filgotinib's effects on sperm cells. https://t.co/SrwInSY45G https://t.co/TD54PXNFbi

Links:

Dr. John Cush RheumNow ( View Tweet)
Antidrug Antibodies Impair Response to Biologic Drugs Monitoring for antidrug antibodies with biologic has not been routine in rheumatology but a new study suggests that antidrug antibodies correlate with nonresponse to bDMARDs in RA patients. https://t.co/tMxZpbyJl1 https://t.co/VCUdkp8I15

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×